CHENGDU,
China and SEATTLE and
LONDON, May 13, 2022
/PRNewswire/ -- BAILI-BIOPHARMACEUTICAL CO., LTD. ("Baili") and its
wholly owned subsidiary, SystImmune, Inc ("SystImmune"), announced
today that it has entered into a clinical trial collaboration and
supply agreement with AstraZeneca (LSE :AZN) (STO: AZN) (NASDAQ :
AZN) to evaluate the combination of Baili's cancer therapy,
SI-B001, an EGFR x HER3 bispecific antibody, in combination with
AstraZeneca's third-generation, irreversible epidermal growth
factor receptor ("EGFR") TKI, TAGRISSO® (osimertinib), in a
new Phase 2a study, sponsored and conducted by Baili, for patients
with non-small cell lung cancer ("NSCLC").
Dr. Yi ZHU, Founder, Chairman, and CEO of Baili commented,
"SI-B001 has demonstrated good tolerability and early sign of
efficacy during Phase 1 trial in China. We are excited about the collaboration
with AstraZeneca to investigate the combination of SI-B001 and a
leading third-generation EGFR TKI for patients with NSCLC. By
combining SI-B001 with Osimertinib, we believe it has the potential
to provide more effective treatment options for patients with
NSCLC."
The financial terms of the non-exclusive collaboration have
not been disclosed.
About SI-B001
SI-B001 is a bispecific antibody designed with the proprietary
platform technology developed by Baili and SystImmune. It can bind
to EGFR and HER3, and simultaneously inhibits the ligand induced
EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and
the activation of its downstream signal pathway. SI-B001 can also
induce endocytosis of EGFR and HER3, and down-regulate the levels
of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has
demonstrated superior tumor killing activities. SI-B001 Phase 1
trials have shown good safety and preliminary efficacy.
About NSCLC and EGFR
Lung cancer is the leading cause of cancer death among men and
women, accounting for about one-fifth of all cancer
deaths. More than a third of the world's lung cancer
patients are in China. Lung cancer
is broadly split into NSCLC and small cell lung cancer, with 80-85%
classified as NSCLC. The majority of NSCLC patients are diagnosed
with advanced disease while approximately 25-30% present with
resectable disease at diagnosis. For patients with
resectable tumors, the majority of patients eventually develop
recurrence despite complete tumor resection and adjuvant
chemotherapy.
Approximately 10-25% of NSCLC patients in the US and
Europe, and 30-40% of patients in
Asia have EGFR-mutated
NSCLC. These patients are particularly sensitive to treatment
with an EGFR TKI which blocks the cell-signaling pathways that
drive the growth of tumor cells.
About Baili
Baili is a biopharmaceutical company focusing on the research
and development, manufacturing, and commercialization of medicines
for cancer and other diseases. With strong R&D teams in both
China and US, it has developed
fully integrated proprietary platforms in bispecific,
multi-specific antibodies and antibody-drug conjugates. Its highly
differentiated platforms have generated a pipeline of six clinical
stage anti-cancer drug candidates. The Company also has
state-of-the-art manufacturing capability designed and built to
meet cGMP standards.
With multiple in-house proprietary platforms for innovative
biopharmaceuticals, Baili has built a robust pipeline to benefit
cancer patients around the world.
View original
content:https://www.prnewswire.com/news-releases/baili-announces-clinical-trial-collaboration-to-evaluate-si-b001-an-egfr-x-her3-bispecific-antibody-in-combination-with-tagrisso-in-patients-with-non-small-cell-lung-cancer-301547299.html
SOURCE SystImmune Inc.